On Feb. 23, 2021, Nabriva Therapeutics announced publication of a study documenting the high rates of macrolide-resistant Streptococcus…
On Jan. 29, 2021, Humanigen announced it had completed enrollment for its pivotal phase 3 study of lenzilumab…
On Jan. 15, 2021, scientists studying the bodyﾒs natural defenses against bacterial infection announced they had identified a…
On Dec. 22, 2020, RedHill Biopharma announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva, ABC294640)1…
On Dec. 8, 2020, Pfizer announced that the FDA accepted for priority review a Biologics License Application (BLA)…
On Nov. 25, 2020, RedHill Biopharma announced partnerships with two leading, U.S.-based manufacturers for large-scale manufacturing of opaganib….
On Nov. 16, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
On Nov. 5, 2020, Novartis announced data from an interim analysis for the randomized, double-blind, placebo-controlled CAN-COVID trial…
On Oct. 13, 2020, RedHill Biopharma announced collaborations with two specialist pharmaceutical manufacturers in Europe and Canada to…
On Oct. 8, 2020, Gilead Sciences and the European Commission signed a joint procurement agreement (JPA) that enabled…
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
On Oct. 7, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…
On Sept. 28, 2020, OpGen announced the successful completion of the clinical study between its subsidiary, Curetis, and…
On Sept. 22, 2020, RedHill Biopharma announced approval from the Brazilian Health Regulatory Agency (ANVISA) for its ongoing…
On Sept. 17, 2020, Roche announced that the phase III EMPACTA study met its primary endpoint, showing that…
On Sept. 15, 2020, the University of Texas Health Science Center at Houston (UTHealth) announced that a study…
On Sept. 14, 2020, at the Pacific Northwest National Laboratory (PNNL) reported that U.S. analysts monitoring global biothreats…
On Sept. 8, 2020, RedHill Biopharma announced that opaganib demonstrated potent inhibition of SARS-CoV-2, the virus that causes…
On Sept. 3, 2020, RedHill Biopharma announced the selection of opaganib, a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2)…
On Aug. 28, 2020, Gilead Sciences announced the FDA expanded the Emergency Use Authorization (EUA) enabling use of…
On Aug. 27, 2020, Myriad RBM announced ultrasensitive immunoassays for viral pneumonia Including COVID-19 from our CLIA-certified laboratory….
On Aug. 27, 2020, RedHill Biopharma announced that its U.S. Phase 2 study with opaganib (Yeliva®, ABC294640) in…
On Aug. 24, 2020, the combination of hydroxychloroquine and azithromycin has been linked to significant cardiovascular risks, including…
On Aug. 19, 2020, an experimental vaccine was reported to be effective at preventing pneumonia in mice infected…
On Aug. 18, 2020, Vanda Pharma reported that interim analysis showed tradipitant may accelerate clinical improvement in SARS-CoV-2…
On Aug. 6, 2020, RedHill Biopharma announced approval from the Mexican Federal Committee for the Protection against Sanitary…
On Jul. 30, 2020, RedHill Biopharma announced that it has initiated a global Phase 2/3 clinical study evaluating…
On Jul. 29, 2020, Roche announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA)…
On Jul. 22, 2020, RedHill Biopharma announced that it had submitted a Clinical Trial Application (CTA) with the…
On Jul. 16, 2020, RedHill Biopharma announced approval from the Ministry of Health of the Russian Federation for…